Filing summary
Entity discrepancy: The request identifies Tvardi Therapeutics, Inc., but the supplied Form 10-Q is for Cara Therapeutics, Inc. The summary below describes Cara’s filing and should not be attributed to Tvardi without verification.
Business context and reporting period
Unaudited quarterly report for the three months ended March 31, 2017, filed May 4, 2017. Cara is a clinical-stage biopharmaceutical company developing CR845-based treatments for pain and pruritus. It had no products for sale; reported revenue came from collaboration, licensing, and clinical-compound arrangements.
Financial performance and position
- Revenue: $0.911 million, versus $0.007 million in Q1 2016. The 2017 total included $0.843 million from Maruishi’s sublicense of CR845 in Japan; $0.598 million was recognized as license and milestone fees and collaborative revenue, and $0.068 million came from clinical-compound sales.
- Losses and expenses: Operating expenses were $23.236 million, including $20.836 million of R&D and $2.400 million of general and administrative expense. Operating loss was $22.325 million and net loss was $22.204 million, compared with a $10.692 million net loss in Q1 2016. Basic and diluted loss per share was $0.81, versus $0.39.
- Cash flow: Operating cash use was $21.636 million, compared with $9.833 million a year earlier. Investing activities provided $14.701 million, mainly from security maturities and sales; financing activities provided $0.149 million from option exercises. Cash and cash equivalents decreased $6.786 million to $5.306 million.
- Liquidity: At March 31, cash and cash equivalents plus marketable securities totaled $36.810 million; another $1.469 million was restricted cash. Current assets were $41.031 million and current liabilities were $12.512 million. Accumulated deficit was $184.420 million.
- Debt and obligations: The balance sheet reports no borrowings at March 31. Future minimum operating lease payments totaled $8.293 million. Accounts payable and accrued expenses were $12.512 million, including $8.861 million accrued for research projects.
- Margins: The filing does not present a gross margin measure; revenue was small relative to development and operating costs.
Material changes and subsequent events
- R&D expense rose 144% year over year, primarily because of higher clinical-trial costs across the Phase 3 I.V. CR845 postoperative-pain program, the Oral CR845 osteoarthritis trial, and the I.V. CR845 uremic-pruritus program. G&A expense decreased 2%.
- On April 5, 2017, after quarter-end, Cara closed a follow-on offering of 5,117,500 shares at $18.00 per share. It reported approximately $86.5 million in net proceeds after underwriting discounts and commissions, but before estimated offering expenses of approximately $0.530 million. The quarter-end balance sheet records the subscription and receivable; the cash was received after quarter-end.
- Including the offering proceeds, management expected available resources to fund anticipated operating expenses and capital expenditures into 2019, excluding potential collaboration milestones. This is an estimate subject to trial timing, costs, and other uncertainties.
Outlook, management commentary, and risks
- Management expected R&D and G&A expenses to remain near then-current levels through 2018, while also anticipating continued significant losses and cash use. It said additional capital would be needed for all development objectives, particularly planned Oral CR845 development.
- Clinical outlook included a planned Q2 2017 interim conditional-power analysis for the postoperative-pain Phase 3 trial; expected Q2 2017 top-line data from the Oral CR845 osteoarthritis Phase 2b and hemodialysis pharmacokinetic trials; and plans to consult the FDA on the next stage of the uremic-pruritus program.
- For uremic pruritus, the company reported that Part A of its Phase 2/3 trial showed a 68% greater reduction in worst-itch scores versus placebo (p<0.0019) and a 100% greater reduction in average Skindex-10 score (p<0.0007). It reported that treatment was generally well tolerated; common adverse events included transient tingling or numbness, somnolence, and dizziness.
- Key risks include clinical-trial success and timing, regulatory approval, manufacturing and commercialization, market acceptance and reimbursement, intellectual-property protection, collaborator and vendor performance, and the ability to raise further capital. The filing says there were no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
- Marketable securities were primarily short-term, investment-grade instruments. Management said a hypothetical 10% interest-rate increase would have an immaterial effect on portfolio fair value; it identified credit-quality deterioration as a risk.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Cara Therapeutics’ 10-Q, not a Tvardi Therapeutics filing.
- Check the April 5 offering’s final net proceeds after offering expenses and the resulting dilution from 5,117,500 new shares.
- Assess whether the projected funding runway into 2019 remains supportable given clinical-trial spending, timing, and the company’s stated need for additional capital for some development objectives.
- Verify subsequent clinical-trial and FDA updates against the milestones and expectations stated in this 2017 filing.